pharma news today obesity drugs glp-1 today A $60 billion industry just found its next growth lever. 💊 With the expiry of a key patent on March 20, 2026, Indian majors are launching generic weight-loss and diabetes GLP-1 Therapies Drive Indian Pharma

This temporary allowance enabled pharmacies to meet surging demand, particularly among patients seeking anti-obesity medications who now represent approximately 83% of the compounded GLP-1 market

Role of the signal peptide in the synthesis and processing of the glucagon-like peptide-1 receptor

INTRODUCTION DKD arises from a complex interplay of metabolic, inflammatory, and hemodynamic disturbances, differing notably between type 1 and type 2 diabetes mellitus [19,20]

Incretin Secretion in Relation to Meal Size and Body Weight in Healthy Subjects and People with Type 1 and Type 2 Diabetes Mellitus

There are two main trials (FIGHT and LIVE trials) demonstrating that treatment with liraglutide increased the risk of adverse heart failure-associated outcomes in patients with heart failure and reduced LVEF [43-45]

0.64% versus 0.14% in the first year) and systolic blood pressure (SBP) (6.8 versus 2.8 mmHg) also decreased, but differences between arms got narrower over time (e.g